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Abstract
Knowledge about antibody-antigen interactions is important for the understanding of the immune system mechanisms and 
for supporting development of drugs and biomarkers. A tool for identification of these antigenic epitopes of specific anti-
bodies is epitope mapping. In this study, a modified enzyme-linked immunosorbent assay was applied for epitope mapping 
of a mouse monoclonal vimentin antibody using overlapping resin-bound peptides covering the entire vimentin protein. 
The minimal epitope required for binding was identified as the lDSlPlVD sequence using N- and C-terminally truncated 
peptides. The peptide sequence lDSlPlVDTH was identified as the complete epitope, corresponding to amino acids 
428–437 in the C-terminal end of the human vimentin protein. Alanine scanning and functionality scanning applying 
substituted peptides were used to identify amino acids essential for antibody reactivity. In particular, the two aspartate 
residues were found to be essential for antibody reactivity since these amino acids could not be substituted without a 
reduction in antibody reactivity. The majority of the remaining amino acids could be substituted without reducing antibody 
reactivity notably. These results confirm that charged amino acids are essential for antibody reactivity and that the vimen-
tin antibody is dependent on side-chain interactions in combination with backbone interactions.
Key Words: Epitope mapping, monoclonal antibody, solid-phase peptide synthesis, synthetic resin-bound peptides
Abbreviations: AP, Alkaline phosphatase; ElISA, Enzyme-linked immunosorbent assay; FITC, Fluorescein isothiocya-
nate; Fmoc, 9-fluorenylmethoxycarbonyl; HoAt, 1-hydroxy-7-aza-benzotriazole; mBl, mannan-binding lectin; NmP, 
N-methyl-2-pyrrolidone; PBS, Phosphate buffered saline; rT, room temperature; SPPS, Solid-phase peptide synthesis; 
TFA, trifluoroacetic acid; TTN, Tris-Tween-NaCl
Introduction
The antigen-antibody interaction is important for 
autoimmune responses and immune responses 
against pathogens. The interface between an 
antibody and its cognate antigen is usually comple-
mentary with regard to structure and size, making 
the interaction highly specific. This interaction 
involves several non-covalent forces [1,2]. Anti-
bodies recognize different motifs in antigens such 
as extended chains, a-helices and b-turns, of which 
the latter are the most common motifs observed in 
B cell epitopes. Antibodies may interact with the 
amino acid side chains of the epitope, the back-
bone atoms or a combination of the two [3–5]. An 
antibody is often highly specific for its epitope, 
which implies that several amino acid side chains 
cannot be replaced without losing antibody 
binding [4].
Antibodies are capable of  recognizing linear and 
conformational B cell epitopes. These epitopes are 
often 10–25 amino acids long, however, some varia-
tion in epitope length has been observed [2,6,7]. 
Epitopes identified tend to be highly accessible on 
the surface of the antigen, hence polar and charged 
amino acids are often found in epitopes. These pref-
erences are most likely due to that polar and charged 
amino acid residues form a variety of interactions 
with the antibodies [6,8]. Several studies have 
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suggested that epitopes have a flexible backbone and 
are located in flexible regions that protrude from the 
protein surface. These properties allow the epitope 
to adopt a conformation that is complementary to 
the structure of the antigen-binding site of the anti-
body [4,6].
Identification of epitopes, also known as epitope 
mapping, provides valuable information about the 
interaction between an antibody and its cognate anti-
gen. The importance of each amino acid in the 
epitope for antibody binding can be determined by 
epitope mapping. Several methods are used for map-
ping of epitopes, depending on whether linear or 
conformational epitopes are mapped. X-ray crystal-
lography is applied for identification of both linear 
and conformational epitopes, however, this approach 
is time consuming and requires large amounts of the 
antigen and antibody to obtain crystals of good qua-
lity. linear epitopes can be mapped by a variety of 
strategies, e.g. enzyme-linked immunosorbent assay 
(ElISA). linear epitopes have been studied more 
extensively than conformational epitopes since they 
are easier to identify and are used for many applica-
tions [3,9]. An efficient strategy for identifying linear 
epitopes by ElISA is to use overlapping synthetic 
peptides covering the entire antigen. This method, 
also referred to as peptide scan, was originally 
described by Geysen et al. [10] in 1984, who deter-
mined a 7-mer epitope of an antibody specific for a 
viral coat protein, which contained two leu residues 
important for antibody binding. Synthetic peptides 
have been used for epitope mapping in several stud-
ies due to their many advantages. They are very pure, 
easily synthesized and chemically or posttranslation-
ally modified amino acids can be incorporated [11]. 
Synthetic resin-bound peptides have been used in a 
few studies for mapping and characterization of B 
cell epitopes [12–14]. The advantage of using resin-
bound peptides is that the peptides are flexible since 
only one amino acid is attached to the solid support. 
Furthermore, using resin-bound peptides instead of 
free peptides, coating steps in ElISA are avoided, 
making this method faster [14,15]. resin-bound 
peptides were originally used for epitope mapping in 
1985 by Paterson [12] who identified two epitopes 
in rat cytochrome c. Synthetic resin-bound peptides 
have also been used in a study by Tian et al. [13] for 
characterization of the 6-mer ElDKWA epitope 
from the gp41 protein of HIV-1 using monoclonal 
antibodies. In the study by Tian et al. [13], charged 
amino acids, such as Asp, and the hydrophobic amino 
acid leu were shown to be important for antibody 
binding. The 9-mer peptide lElDKWASl was 
identified as the complete epitope attaining maximal 
affinity [13]. These types of epitope mapping studies 
provide knowledge about the location of epitopes 
within an antigen and are important for the develo-
pment of diagnostic kits, design of vaccines and 
immunotherapy. Furthermore, determination and 
characterization of epitopes are also important for 
understanding the pathophysiology of many diseases, 
including autoimmune diseases [6,16].
Several epitopes have been described in multiple 
proteins, such as vimentin, which is a protein subunit 
of intermediate filaments found in mesenchymal 
cells [17,18]. Vimentin is a part of the cytoskeleton 
and is involved in stabilization of the molecular net-
work. moreover, vimentin functions in organelle 
transport, cell migration and proliferation. The broad 
range of physiological functions of vimentin is also 
underlined by the intracellular and extracellular 
localization as well as the possibility of modifications 
such as phosphorylation and citrullination [19–21]. 
Antibodies targeting modified vimentin have been 
suggested to have a role in the autoimmune disease 
rheumatoid arthritis and are used as a marker for 
diagnosis of the disease [22,23].
In this study, the epitope of a mouse monoclonal 
vimentin antibody was fine mapped using overla-
pping synthetic resin-bound vimentin peptides. 
The identified epitope of the vimentin antibody was 
further characterized using both truncated peptides 
and substituted peptides. moreover, the substituted 
peptides were applied to examine which kinds of 
modifications the antibody was able to tolerate.
Materials and methods
Reagents
overlapping resin-bound vimentin peptides, C- 
terminally truncated resin-bound peptides and sub-
stituted peptides were purchased from Schafer-N. 
N-terminally truncated vimentin peptides were syn-
thesized by 9-fluorenylmethoxycarbonyl (Fmoc)-
based solid-phase peptide synthesis (SPPS) as 
described below. Tris-Tween-NaCl (TTN) buffer 
(0.0 5m Tris, 0.3 m NaCl, 1% Tween 20, pH 7.4), 
alkaline phosphatase (AP) substrate buffer (1 m 
diethanolamine, 0.5 mm mgCl2, pH 9.8), phosphate 
buffered saline (PBS, pH 7.2), glycerol and mouse 
monoclonal human mannan-binding lectin (mBl) 
antibody (HYB 131-01) were from Statens Serum 
Institut. AP-conjugated anti-mouse IgG (A3688), para-
nitrophenylphosphate, N,N ′-diisopro pylcarbodiimide, 
piperidine, trifluoroacetic acid (TFA), ethanol and 
ether were purchased from Sigma-Aldrich. mouse 
monoclonal human vimentin antibody was 
purchased from Biosite (AmB-7100). TentaGel S NH2 
resin was purchased from rAPP Polymere GmbH 
(S30902). Fmoc-protected amino acids and N- 
methyl-2-pyrrolidone (NmP) were purchased from 
Iris Biotech GmbH. 1-hydroxy-7-aza-benzotriazole 
(HoAt) was purchased from Gl Biochem. Triiso-
propylsilane was purchased from merck; a 13-well 
HEp-2 slides ANA Test system HEp-2 substrate was 
purchased from Immuno Concepts (rEF2013). 
Fluorescein isothiocyanate (FITC)-conjugated anti-
mouse IgG was purchased from Dako (F0261).
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Peptides
overlapping resin-bound vimentin peptides, spanning 
the complete human vimentin sequence (Accession 
number: P08670), were constructed as 20-mer pep-
tides with a 10 amino acid overlap. In total 46 pep-
tides were generated (See Supplementary Appendix 
to be found online at http://informahealthcare.com/
doi/abs/10.3109/00365513.2014.908474).
Indirect immunofluorescence
Slides with HEp-2 cells were incubated with pri-
mary antibody (vimentin antibody or control mBl 
antibody) diluted in PBS (1:160–1:2560). The 
slides were incubated in a humidity chamber at 
room temperature (rT) for 30 min. The HEp-2 
slides were then washed 5 times with PBS followed 
by 10 min incubation at rT in PBS. FITC-conju-
gated anti-mouse IgG diluted in PBS (1:40) was 
added to the slides and incubated in a humidity 
chamber at rT for 30 min followed by a PBS wash 
for 10 min. After wiping the slides, glycerol was 
added as a mounting medium and the wells were 
covered with a cover glass. The slides were analyzed 
using an olympus DP72 fluorescence microscope 
(olympus, PA, uSA).
Solid-phase peptide synthesis of N-terminally  
truncated peptides
N-terminally truncated resin-bound peptides, 
using the sequence rETNlDSlPlVDTH from 
vimentin as template, were synthesized by tradi-
tional Fmoc-based SPPS as described previously 
[24]. Briefly, 20 mg resin was removed from the 
resin pool after coupling of each amino acid except 
for the first three amino acids. 12 N-terminally 
truncated resin-bound peptides were synthesized 
in total. The peptides were synthesized in a syringe 
using TentaGel S NH2 resin (270 mg, loading 
capacity 0.31 mmol/g). Amino acid activation and 
coupling was conducted using three-fold excess of 
Fmoc-protected amino acids, HoAt and N,N′-
diisopropylcarbodiimide. All amino acids were 
double coupled for at least 2.5 h in total at rT 
with a NmP wash between the two couplings. 
Following coupling, the resin was rinsed 7 times 
with NmP and deprotection was conducted using 
20% piperidine in NmP 3 times for 17 min in 
total. Following synthesis of the peptides, the resin 
was washed twice with ethanol and ether, respec-
tively. The side chain protection groups were 
removed using a 5% triisopropylsilane and 95% 
TFA solution for 2 h at rT. The resin-bound pep-
tides were rinsed twice with TFA and three times 
with ether and the remaining ether was evaporated 
over-night.
Modified enzyme-linked immunosorbent assay
The resin-bound peptides (3.3 mg/ml resin) 
were added to a 96-well multiscreen HTS filter plate 
(millipore, Copenhagen, Denmark) and washed with 
TTN buffer using a multiscreen vacuum manifold 
(millipore, Copenhagen, Denmark). The wells 
were blocked with TTN buffer for 20 min at rT. 
Primary mouse monoclonal antibody directed against 
vimentin or mBl (1:1000) was added and the 
plate was incubated for 1 hour at rT on a shaking 
table. Secondary AP-conjugated anti-mouse IgG 
(1:1000) was added and the plate was incubated for 
1 h at rT on a shaking table. Both incubations with 
antibodies were followed by 4 washes with TTN 
buffer. For quantification of bound antibodies, para-
nitrophenylphosphate (1 mg/ml) diluted in AP 
substrate buffer was used. The buffer was transferred 
to a maxisorp microtitre plate (Nunc, roskilde, 
Denmark) and the absorbance was determined at 
405 nm, with background subtraction at 650 nm, 
using a Thermomax microtitre plate reader (molecular 
Devices, menlo Park, CA, uSA).
Results
Confirmation of antibody specificity
The monoclonal antibody directed against vimentin 
was tested by indirect immunofluorescence to check 
the specificity of the antibody. The reactivity of the 
monoclonal vimentin antibody to HEp-2 cells 
revealed a typical vimentin pattern [25,26], confirm-
ing the specificity for vimentin (Figure 1). No pat-
terns were detected with the control antibody directed 
against mBl.
Screening of vimentin peptides with a monoclonal 
vimentin antibody
To identify a potential epitope within the vimentin 
protein, the vimentin antibody was screened for reac-
tivity to 46 overlapping resin-bound vimentin pep-
tides by modified ElISA. A monoclonal control 
antibody of irrelevant specificity directed against 
mBl was used as a negative control.
As illustrated in Figure 2, the monoclonal 
vimentin antibody recognized two peptides, peptide 
2 (YrrmFGGPGTASrPSSSrSY, 11–30) and pep-
tide 43 (lNlrETNlDSlPlVDTHSKr, 421–440). 
moreover, the control antibody of irrelevant specificity 
was found to recognize peptide 2 as well, indicating 
that antibody reactivity to peptide 2 was nonspecific. 
Thus, specific reactivity was only obtained to peptide 
43, suggesting that the epitope of the vimentin 
antibody is located within peptide 43. Furthermore, 
no reactivity was observed with peptides 42 and 44, 
indicating that the epitope spans the overlap of these 
two peptides.
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Identification of terminal epitope borders using N- and 
C-terminally truncated resin-bound peptides
In order to determine the minimal epitope essential 
for antibody reactivity within peptide 43, N-terminally 
truncated resin-bound peptides, using peptide 43 as 
template, were synthesized by Fmoc-based SPPS 
and the vimentin antibody was tested for reactivity to 
the peptides by modified ElISA. As shown in Figure 
3A, no interaction was observed between the vimentin 
antibody and the seven shortest peptides (DTH-
DSlPVDTH). The peptide lDSlPlVDTH was the 
shortest resin-bound peptide found to interact with 
the vimentin antibody. This result indicated that the 
N-terminal leu of lDSlPlVDTH was important 
for antibody reactivity. The interaction between the 
antibody and the peptides longer than lDSlPlVDTH 
showed almost no further increase in antibody 
re activity compared to the control (peptide 43).
Based on these findings, antibody reactivity 
to C-terminally truncated vimentin peptides was 
studied by modified ElISA using lDSlPlVDTH 
as a template. As seen in Figure 3B, only two of the 
C-terminally truncated peptides were recognized by 
the vimentin antibody. The antibody showed no reac-
tivity to the five shortest peptides (lDS-lDSlPlV). 
lDSlPlVD was the shortest peptide recognized by 
the vimentin antibody, indicating that the C-terminal 
Asp was important for antibody reactivity. To sum 
up, the terminal truncation studies suggested that 
lDSlPlVD was the minimal epitope of the vimen-
tin antibody.
Screening of epitope candidates for identification  
of the complete epitope
Based on the results from the initial screenings of 
N- and C-terminally truncated vimentin peptides, 
the complete epitope of the vimentin antibody was 
identified by screening selected epitope candidates 
using modified ElISA.
As demonstrated in Figure 4, lDSlPlVD was the 
shortest peptide found to interact with the antibody, 
Figure 2. reactivity of a mouse monoclonal vimentin antibody and mBl antibody to 46 overlapping resin-bound vimentin peptides 
analyzed by modified ElISA. Negative control: peptide of irrelevant specificity was used. The sequence for the negative control peptide 
is shown in the Supplementary Appendix to be found online at http://informahealthcare.com/doi/abs/10.3109/00365513.2014.908474. 
Antibody reactivity to each peptide was analyzed in duplicate. relative to controls specific antibody reactivity was found to peptide 43.
Figure 1. reactivity of antibodies directed against vimentin and 
mannan-binding lectin to HEp-2 cells analyzed by indirect 
immunofluorescence. (A) Vimentin antibody, diluted 1:2560. (B) 
mannan-binding lectin antibody, diluted 1:160. This Figure is 
reproduced in colour in the online version of The Scandinavian 
Journal of Clinical & Laboratory Investigation.
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supporting the finding that this peptide was the min-
imal epitope of the vimentin antibody. A small increase 
in antibody reactivity (approx. 20%) was observed 
from lDSlPlVD to lDSlPlVDT and similarly 
from lDSlPlVDT to lDSlPlVDTH, indicating 
that the C-terminal Thr and His were also important 
for antibody reactivity. These results suggested that the 
amino acid sequence lDSlPlVDTH constituted the 
complete epitope of the vimentin antibody.
Analysis of the vimentin antibody epitope  
by alanine scanning
In order to identify the amino acids of the epitope 
that were essential for antibody binding, an Ala scan-
ning was performed by modified ElISA. The peptide 
N1lDSlPlVDTH11 (numbers indicate position of 
amino acids in the peptide) was used as template for 
generation of Ala-substituted peptides.
As illustrated in Figure 5, antibody reactivity to 
the peptides, where Asp3 and Asp9 were substi-
tuted with Ala, was almost completely reduced 
(89–97% reduction), compared to the control pep-
tide NlDSlPlVDTH. This indicated that these 
amino acids were essential for reactivity with the 
vimentin antibody. Furthermore, a notable reduc-
tion in antibody reactivity was observed when leu2 
and leu5 were substituted with Ala, suggesting 
that they also influenced antibody binding. Substi-
tution of the remaining amino acids with Ala yielded 
nearly no difference in reactivity compared to the 
control peptide, suggesting that the side chains of 
Figure 3. (A) reactivity of the vimentin antibody to N-terminally truncated resin-bound vimentin peptides and (B) C-terminally truncated 
resin-bound vimentin peptides measured by modified ElISA. Peptide 43 (lNlrETNlDSlPlVDTHSKr) was used as a positive control. 
uncoated resin was used as a negative control. Antibody reactivity to each peptide was analyzed in duplicate.
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these amino acids were not involved in the binding 
to the vimentin antibody.
Analysis of vimentin antibody reactivity  
to functional-substituted peptides
In order to examine which kind of substitutions that 
were tolerated by the vimentin antibody in each posi-
tion of the identified epitope, a functionality scan-
ning was performed, in which each amino acid in the 
peptide sequence was substituted with different 
amino acids, mainly with amino acids with similar 
side chain functionality or size. The influence of these 
varying substitutions on antibody reactivity to the 
NlDSlPlVDTH peptide was analyzed by a modified 
ElISA.
Figure 6 illustrates antibody reactivity to substi-
tuted peptides. As illustrated, when substituting 
Asp3 with either Glu or Asn, antibody reactivity was 
reduced by approx. 100% compared to the control 
peptide NlDSlPlVDTH. Substitution of Asp9 
with Asn resulted in approximately 80% reduction 
compared to the control peptide. When leu5 was 
substituted with Ile or Val a reduction of approxi-
mately 50% and 70%, respectively, was observed. 
The substitution of Pro6 with Gly resulted in a very 
large reduction, almost 100% compared to the control 
peptide.
These results suggested that Asp3, Asp9, leu5 
and Pro6 were important for antibody reactivity. In 
contrast, substitution of the amino acids in the 
remaining positions only showed a slight reduction 
in reactivity, indicating that these specific amino 
acids were not important for antibody binding.
Discussion
In this study, the reactivity of a monoclonal vimentin 
antibody to overlapping resin-bound peptides, cover-
ing the entire human vimentin protein sequence, was 
analyzed in order to locate and characterize the 
epitope. Peptide 43, corresponding to amino acids 
lNlrETNlDSlPlVDTHSKr (position 421–440) 
was the only peptide specifically recognized by the 
antibody, as illustrated in Figure 2. The epitope was 
assumed to involve the middle of the 20-mer peptide, 
since only one peptide was recognized in a specific 
manner and the two neighboring peptides showed no 
reactivity. Based on these findings, N- and C-terminally 
truncated peptides were generated and analyzed for 
antibody reactivity, identifying the peptide lDSlPlVD 
as the minimal epitope. These findings indicated that 
the N-terminal leu and the C-terminal Asp were 
important for antibody recognition (Figure 3). Fur-
ther studies identified the amino acid sequence 
lDSlPlVDTH as the complete epitope, suggesting 
that the C-terminal Thr and His were important but 
not essential for antibody binding (Figure 4).
The identified vimentin epitope was found to be 
located in the tail region of vimentin. As no crystal 
structure, covering this particular region of human 
vimentin, is available, the secondary structure of this 
region has not been determined. Nevertheless, a study 
by Hess et al. [27], using site directed spin labeling 
and electron paramagnetic resonance, revealed that 
most of the vimentin tail region is disordered and 
have a higher degree of flexibility compared to the 
head and rod domains of the vimentin protein [27]. 
The indication of a flexible tail of the vimentin protein 
is supported by other studies [28,29]. Furthermore, 
Figure 4. reactivity of the vimentin antibody to resin-bound 
vimentin epitope candidates analyzed by modified ElISA. 
Peptide 43 (lNlrETNlDSlPlVDTHSKr) was used as a 
positive control. The peptide lDSlPlV and uncoated resin were 
used negative controls. Antibody reactivity to each peptide was 
analyzed in duplicate.
Figure 5. reactivity of the vimentin antibody to Ala-substituted 
resin-bound vimentin peptides analyzed by modified ElISA. The 
peptide NlDSlPlVDTH was used as the positive control peptide 
with no substitutions. uncoated resin was used as a negative 
control. Antibody reactivity to each peptide was analyzed in 
duplicate.
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acid with an aliphatic side chain similar to the one 
in leu is sufficient to retain antibody reactivity. The 
side chain of Ala is shorter than that of leu and Ala 
was not sufficient to retain antibody reactivity as 
seen in the Ala scanning. Substitution of leu5 with 
Ile or Val resulted in a large reduction in antibody 
reactivity as seen in Figure 6, indicating the impor-
tance of the specific leu side chain in this position. 
The leu residues may contribute with van der Waals 
interactions. The importance of leu residues for 
antibody reactivity was also confirmed by other 
studies [10,13].
moreover, substitution of Pro6 with Gly resulted 
in a very large reduction in antibody reactivity. Gly 
is a very flexible amino acid in contrast to Pro, which 
is a very rigid amino acid. This result may indicate 
that the Pro residue is important for the structure of 
the peptide, by constraining the peptide in a rather 
inflexible structure, since antibody reactivity was not 
reduced upon substitution with Ala which is not as 
flexible as Gly. The presence of Pro may indicate that 
the epitope is located in a b-turn since Pro is often 
seen in b-turns. This is in agreement with b-turns 
being the predominant motif in peptide-antibody 
complexes [4,31].
Substitution of the remaining amino acids with 
various amino acids of similar or dissimilar side chain 
functionality including Ala showed nearly no reduc-
tion in antibody reactivity, suggesting that the side 
chains of these amino acids are not involved in direct 
interactions with the antibody. However, these amino 
acids may contribute to the conformation of the pep-
tide which is important for proper antigen presenta-
tion or they may contribute with backbone interactions 
to the antibody.
In this epitope mapping study, we demonstrated 
that screening overlapping synthetic resin-bound 
peptides, covering a whole protein, with a mono-
clonal antibody is an efficient method for identifica-
tion and mapping of epitopes in antigens targeted 
computer models have been used for predicting the 
secondary structure of the vimentin tail and they sug-
gested extended strand and random coil [27,28]. 
These studies indicate that the identified vimentin 
epitope is found in a flexible region and this is a typ-
ical feature of antibody epitopes [6].
The epitope of the vimentin antibody was further 
characterized by Ala scanning and functionality scan-
ning of the peptide NlDSlPlVDTH. As illustrated, 
the two negatively charged Asp3 and Asp9 residues 
were important for antibody binding (Figures 5 and 
6). It was not possible to substitute Asp3 with Ala, 
Glu (similar functional group) or Asn (similar size), 
without notable influence on antibody reactivity, 
indicating a direct interaction between the Asp side 
chain and the antibody. These findings indicate that 
even small changes in this position disrupt the inter-
action between the epitope and the antibody, making 
this residue essential for antibody reactivity. In con-
trast, the Asp9 residue could be replaced with Glu 
without affecting the antibody reactivity, which may 
suggest that only the negative charge and not the 
specific side chain of Asp is important for reactivity 
in this position. The results obtained are in accor-
dance with previous studies, showing that charged 
residues are important for antibody reactivity 
[6,24,30]. Furthermore, the results confirmed that 
the C-terminal Asp residue of the minimal epitope is 
important for antibody recognition. The two Asp 
residues were found to be the most important amino 
acids of the epitope for antibody reactivity and they 
may form ionic interactions and hydrogen bonds 
with the antibody.
In addition, the two hydrophobic leu2 and 
leu5 residues were also shown to be important for 
antibody binding, as seen by a notable reduction in 
antibody reactivity upon Ala substitution. In con-
trast to the results of the Ala scanning, substitution 
of leu2 with Ile or Val did not influence antibody 
reactivity, suggesting that the presence of an amino 
Figure 6. reactivity of the vimentin antibody to substituted resin-bound vimentin peptides analyzed by modified ElISA. The peptide 
NlDSlPlVDTH was used as the control peptide with no substitutions. uncoated resin was used as a negative control. Antibody reactivity 
to each peptide was analyzed in duplicate.
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temic rheumatic diseases. Clin Chim Acta 2004;340:1–25.
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Identification of continuous epitopes of HuD antibodies 
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antigen-fragment libraries for epitope mapping and the 
development of vaccines and diagnostics. Curr opin Chem 
Biol 2001;5:314–24.
Fidlerová H, Sovová V, Krekule I, Viklický V, levan G. [17] 
Immunofluorescence detection of the vimentin epitope in 
chromatin structures of cell nuclei and chromosomes. 
Hereditas 1992;117:265–73.
Kouklis PD, Traub P, Georgatos SD. Involvement of the [18] 
consensus sequence motif at coil 2b in the assembly and 
stability of vimentin filaments. J Cell Sci 1992;102:31–41.
mor-Vaknin N, Punturieri A, Sitwala K, markovitz Dm. [19] 
Vimentin is secreted by activated macrophages. Nature Cell 
Biol 2003;5:59–63.
Pixley SK, Kobayashi Y, de Vellis J. A monoclonal antibody [20] 
against vimentin: characterization. Brain res 1984;317: 
185–99.
osung oA, Chandra m, Holborow EJ. Intermediate [21] 
filaments in synovial lining cells in rheumatoid arthritis and 
other arthritides are of vimentin type. Ann rheum Dis 1982; 
41:74–7.
Vossenaar E, Després N, lapointe E, van der Heijden A, [22] 
lora m, Senshu T, van Venrooij WJ, menard HA. rheuma-
toid arthritis specific anti-Sa antibodies target citrullinated 
vimentin. Arthritis res Ther 2004;6:r142–50.
Bang H, Egerer K, Gauliard A, lüthke K, rudolph PE, [23] 
Fredenhagen G, Berg W, Feist E, Burmester G-r. mutation 
and citrullination modifies vimentin to a novel autoantigen 
for rheumatoid arthritis. Arthritis rheum 2007;56:2503–11.
Petersen NH, Hansen Pr, Houen G. Fast and efficient [24] 
characterization of an anti-gliadin monoclonal antibody 
epitope related to celiac disease using resin-bound peptides. 
J Immunol methods 2011;365:174–82.
Wiik AS, Hoeier-madsen m, Forslid J, Charles P, [25] 
meyrowitsch J. Antinuclear antibodies: a contemporary nomen-
clature using HEp-2 cells. J Autoimmun 2010;35:276–90.
Price AS, Keil lB, DeBari VA. Immunocytochemical [26] 
localization of cytoskeletal antigens in KB and HEp-2 cells. 
Diagn Clin Immunol 1988;5:400–13.
Hess JF, Budamagunta mS, Aziz A, FitzGerald PG, Voss JC. [27] 
Electron paramagnetic resonance analysis of the vimentin 
tail domain reveals points of order in a largely disordered 
region and conformational adaptation upon filament assem-
bly. Protein Sci 2013;22:47–55.
Strelkov SV, Herrmann H, Geisler N, Wedig T, Zimbelmann r, [28] 
Aebi u, Burkhard P. Conserved segments 1A and 2B of the 
intermediate filament dimer: their atomic structures and 
role in filament assembly. EmBo J 2002;21:1255–66.
by antibodies. Determination of epitopes and charac-
terization of the antibody-antigen interaction are 
relevant for diagnostics and treatment of several dis-
eases as well as development of vaccines [16,32]. 
moreover, discovery of new antigenic targets using 
epitope mapping may aid in understanding of 
the pathophysiology of different diseases, e.g. auto-
immune diseases involving autoantibodies [7,33,34].
To sum up, in this study only a single peptide was 
recognized in a specific manner by the vimentin anti-
body and the minimal and the complete epitope were 
determined to be the amino acid sequences 
lDSlPlVD and lDSlPlVDTH, respectively. Ala 
scanning and functionality scanning suggested that 
the two charged Asp residues were the amino acids 
most essential for antibody binding, underlining the 
importance of charged amino acids in epitopes.
The screening approach applied in this study is 
primarily based on detection of linear epitopes, due 
to practical limitaions, e.g. peptide length. It is 
unlikely that this type of assay could be applied for 
detection of conformational epitopes with great suc-
cess. However, by applying longer peptides and to 
pool resin-bound peptides within wells, it may be 
possible to determine antigenicity within selected 
regions, e.g. domains. Thus when applying approaches 
like this in studying biomarkers analyzed by immuno-
chemical methods, it only relates to antibodies 
detecting linear epitopes. 
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